Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

Autor: Mateos, Maria-Victoria, Blacklock, Hilary, Schjesvold, Fredrik, Oriol, Albert, Simpson, David, George, Anupkumar, Goldschmidt, Hartmut, Larocca, Alessandra, Chanan-Khan, Asher, Sherbenou, Daniel, Avivi, Irit, Benyamini, Noam, Iida, Shinsuke, Matsumoto, Morio, Suzuki, Kenshi, Ribrag, Vincent, Usmani, Saad Z, Jagannath, Sundar, Ocio, Enrique M, Rodriguez-Otero, Paula, San Miguel, Jesus, Kher, Uma, Farooqui, Mohammed, Liao, Jason, Marinello, Patricia, Lonial, Sagar, KEYNOTE-183 Investigators, Nicol A, Grigoriadis G, Catalano J, LeBlanc R, Elemary M, Bahlis N, Facon T, Karlin L, Ribrag V, Attal M, Goldschmidt H, Engelhardt M, Weisel K, Mackensen A, Nagler A, Ben Yehuda D, Avivi I, Benyamini N, Magen-Nativ H, Palumbo A, Cavo M, Tobinai K, Iida S, Chou T, Suzuki K, Kosugi H, Taniwaki M, Sunami K, Matsumoto M, Ando K, Ganly P, Blacklock H, Simpson D, George A, Schjesvold F, Gjertsen B, Lahuerta J, Blade J, Oriol Rocafiguera A, Mateos M, Rodriguez-Otero P, Larson S, Atanackovic D, Devarakonda S, Bitran J, Zonder J, Morganstein N, Hay M, Chanan-Khan A, Saylors G, Kio E, Oliff I, Kirkel D, Shtivelband M, Yuen C, Yee A, Shah J, Htut M, Raza S, Chhabra S, Stiff P, Hari P, Bank B, Malek E, Gasparetto C, Faroun Y, Sherbenou D, Kreisle W, Singhal S, Rosenblatt J, Usmani S, Lee W, Safah H, Lutzky J, Suh J, Pan D, Baron A, Manges R, Steis R, Oliveira M, Moreb J, Callander N, Anz B, Raptis A, Stampleman L, Melear J, Boyd T, Garbo L, Klein L, Shao S, Lyons R, McIntyre K, Tarantolo S, Yasenchak C, Yimer H.

Publikováno v: Ann Transl Med
Lancet Haematology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

Summary Background Pomalidomide and dexamethasone is a standard of care for patients with multiple myeloma in whom bortezomib and lenalidomide treatment has failed. KEYNOTE-183 assessed efficacy and safety of pomalidomide and dexamethasone with or wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21f1362cea0664cfe2470bd04f49b410
https://hdl.handle.net/2318/1742132

Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer

Autor: Urba, W. J., Steis, R. G., Longo, D. L., Kopp, W. C., Maluish, A. E., Marcon, Luisa, Nelson, D. L., Stevenson, H. C., Clark, J. W.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3657::b4e3df9174486f9c83fb3aa97eea64a5
http://hdl.handle.net/11577/122426

Myocarditis or acute myocardial infarction associated with interleukin-2 therapy for cancer.

Autor: Kragel, Amy H., Travis, William D., Steis, Ronald G., Rosenberg, Steven A., Roberts, William C., Kragel, A H, Travis, W D, Steis, R G, Rosenberg, S A, Roberts, W C

Publikováno v: Cancer (0008543X); Oct1990, Vol. 66 Issue 7, p1513-1516, 4p

Clinical course and prognosis of the lymphoproliferative disease of granular lymphocytes. A multicenter study.

Autor: Pandolfi, F., Loughran, T. P., Starkebaum, G., Chisesi, T., Barbui, T., Chan, W. C., Brouet, J. C., de Rossi, G., McKenna, R. W., Salsano, F., Herrmann, F., Vanoostveen, J. W., Schlimok, G., Cafaro, A., Zambello, R., Garcia Rodriguez, M. C., Geisler, C. H., Pizzolo, G., Steis, R. G., Brisbane, J. U.

Publikováno v: Cancer (0008543X); Jan1990, Vol. 65 Issue 2, p341-348, 8p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.